Literature DB >> 9674761

Pharmacologic treatment of cognition in Alzheimer's dementia.

M R Farlow1, R M Evans.   

Abstract

Much of the treatment research and development for Alzheimer's disease (AD) in recent years has been based on the cholinergic hypothesis. Cholinesterase inhibition has been shown to improve the symptoms of mild to moderate AD. Two cholinesterase inhibitors (CIs) are now available and two more may be available shortly. Free radical inhibitors, estrogen, and anti-inflammatory drugs may also delay the onset and slow progression of AD. Combination therapies employing CIs and these other drugs may prove successful in the future.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674761     DOI: 10.1212/wnl.51.1_suppl_1.s36

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Verbal fluency performance in amnestic MCI and older adults with cognitive complaints.

Authors:  Katherine E Nutter-Upham; Andrew J Saykin; Laura A Rabin; Robert M Roth; Heather A Wishart; Nadia Pare; Laura A Flashman
Journal:  Arch Clin Neuropsychol       Date:  2008-03-12       Impact factor: 2.813

Review 2.  Alterations in Cholinergic Pathways and Therapeutic Strategies Targeting Cholinergic System after Traumatic Brain Injury.

Authors:  Samuel S Shin; C Edward Dixon
Journal:  J Neurotrauma       Date:  2015-06-29       Impact factor: 5.269

Review 3.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

4.  Frontiers in Alzheimer's disease therapeutics.

Authors:  Jeremy G Stone; Gemma Casadesus; Kasia Gustaw-Rothenberg; Sandra L Siedlak; Xinglong Wang; Xiongwei Zhu; George Perry; Rudy J Castellani; Mark A Smith
Journal:  Ther Adv Chronic Dis       Date:  2011-01-01       Impact factor: 5.091

Review 5.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

Review 6.  Recent developments in the drug treatment of Alzheimer's disease.

Authors:  J J Sramek; N R Cutler
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 7.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.

Authors:  K Rockwood; J Mintzer; L Truyen; T Wessel; D Wilkinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

Review 9.  Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease.

Authors:  Kjell Någren; Christer Halldin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-22       Impact factor: 9.236

10.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.